Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia.
about
Antifungal resistance in pathogenic fungiEpidemiology of invasive candidiasis: a persistent public health problemInternational surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobiaGrowth inhibition and ultrastructural alterations induced by Delta24(25)-sterol methyltransferase inhibitors in Candida spp. isolates, including non-albicans organismsDetection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates: performances of three different media assessed by using E-test and National Committee for Clinical Laboratory Standards M27-A methodologiesStable phenotypic resistance of Candida species to amphotericin B conferred by preexposure to subinhibitory levels of azoles.Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance.Correlation between in vitro activity of posaconazole and in vivo efficacy against Rhizopus oryzae infection in mice.Influence of incubation time, inoculum size, and glucose concentrations on spectrophotometric endpoint determinations for amphotericin B, fluconazole, and itraconazole.In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole.Optimizing voriconazole susceptibility testing of Candida: effects of incubation time, endpoint rule, species of Candida, and level of fluconazole susceptibility.Improved detection of amphotericin B-resistant isolates of Candida lusitaniae by EtestPrevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: results of a 2-year (1996 to 1998) multicenter surveillance study in Quebec, Canada.Antifungal susceptibility testing: practical aspects and current challenges.Amphotericin B and fluconazole affect cellular charge, macrophage phagocytosis, and cellular morphology of Cryptococcus neoformans at subinhibitory concentrationsCorrelation between in vitro susceptibility determined by E test and response to therapy with amphotericin B: results from a multicenter prospective study of candidemia.In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatumPharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis modelDetection of resistance to amphotericin B in Candida isolates by using Iso-Sensitest broth.Antifungal pharmacodynamics: review of the literature and clinical applications.Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study.First three reported cases of nosocomial fungemia caused by Candida aurisOptimal testing conditions for determining MICs and minimum fungicidal concentrations of new and established antifungal agents for uncommon molds: NCCLS collaborative study.Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century.Approaches to fungal diagnosis in transplantation.In vitro antifungal susceptibility testing.Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo.In vitro activity of nystatin compared with those of liposomal nystatin, amphotericin B, and fluconazole against clinical Candida isolatesNationwide sentinel surveillance of bloodstream Candida infections in 40 tertiary care hospitals in SpainEvaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcomeEpidemiology of candidemia in Latin America: a laboratory-based survey.Has antifungal susceptibility testing come of age?Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centersPreclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90Genetically recombinant antibodies: new therapeutics against candidiasis.Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002.Clinical impact of the fungicidal activity of caspofungin administered alone or in combination in critically ill patients with severe abdominal candidiasis refractory to conventional antifungal drugs: case studies and critical review of the problem.Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization.FREQUENCY OF Candida SPECIES IN A TERTIARY CARE HOSPITAL IN TRIANGULO MINEIRO, MINAS GERAIS STATE, BRAZIL.Detection of amphotericin B resistance in Candida haemulonii and closely related species by use of the Etest, Vitek-2 yeast susceptibility system, and CLSI and EUCAST broth microdilution methods
P2860
Q28208165-08BC89C7-49CB-496A-8576-679AD6D42A03Q29616758-0FC72805-4CD8-4973-8DBF-9BA0F3E8CF08Q30453797-141A6AFE-EB6D-49CE-8324-1B4A7CC74C64Q33432326-C040125D-E002-4D8D-BF02-39E243E2D7D0Q33677651-1CA838A5-BC91-40E0-A307-A6F883B911E1Q33683250-84C56797-69E0-4954-90E2-B25BB03DCE49Q33805788-A3D53C4C-6A2D-4AA1-81E5-BD12D220E616Q33826450-CCF72ECE-1FD6-4FA7-9904-F90AD28ECA3FQ33958121-C940E1AE-9CC9-4C28-BCC7-13091645DE74Q33961573-1774E54B-34E5-4B49-BFF2-46FB446FBA0AQ33962343-4B963E28-32B6-47D6-90F3-5853F94041DBQ33971002-09FAD8E7-6DDC-485D-8F83-0AEBBC8EE074Q33971521-37FBD9BC-2A12-4F42-90B3-1A100D9C51D9Q33975757-0F13380D-B7B1-4A12-A90B-29C4797DF3F3Q33975989-47BFBBD0-E76A-4C18-B8AA-C0DAE4A07788Q33976842-DF785A1A-62DE-4414-B28A-167974B4FB4BQ33979873-68FA346C-EBAD-4FD3-9D29-FE216F099F74Q33981712-2C2B1193-7281-4C85-A363-24C5AEB9BB37Q33982529-93D1B0AB-8409-421E-94C9-DF7842EC8C15Q34083129-9A8256E5-EAA8-429B-965D-19056E534851Q34195380-3DBFC955-391A-41FC-9050-7EA05EE67907Q34196357-6FD12261-47F5-467B-88DD-42CB9C2294D2Q34202213-D0AB2D40-CB38-42BE-865F-B631D7C432A6Q34294875-58A467B4-AFA5-4FF0-BB95-173E4536EFB4Q34294880-3F8516C3-0D90-4537-9B70-A70829FBF29CQ34335217-09D7AA5A-D99F-4B9B-89EB-0EDCFCDE2067Q34335230-5D003B60-7DC2-43BC-B1DB-0FE61AED7AB3Q34452652-11B88208-A202-4025-8790-0DF9E9B3FF99Q34489579-5FDEB5B9-A527-4582-9B8D-03113B03AFEDQ34510359-EB616177-9CC0-40F3-B342-7142721C21A1Q34635088-C5F2E658-3FC7-4F7D-A981-8C3E0CD18F09Q34923038-80303BBC-0839-4AC3-828D-7F3EE5A1453BQ35073043-579A4811-CA46-464D-A8C1-989817B781C9Q35102525-4BE3AAB5-4CBB-4F3A-95CB-6DD9802366BCQ35681522-554D1511-790D-4F2F-8C0B-2616053F1618Q35714132-2DD0CA11-6D24-4D6F-80A3-C726E0FA9E56Q35738800-D2333F3C-5BFB-49A3-BFA8-0B4F79870C57Q35745822-C2825913-D830-467A-B724-3AFEF36DDFCDQ35980145-ED7CC3BE-33E5-45CF-8A6C-1F28BAAD73DDQ36022880-20A28389-64A6-41AD-8B4A-CFE211A1FE46
P2860
Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia.
description
1998 nî lūn-bûn
@nan
1998 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Do in vitro susceptibility dat ...... atients with Candida fungemia.
@ast
Do in vitro susceptibility dat ...... atients with Candida fungemia.
@en
type
label
Do in vitro susceptibility dat ...... atients with Candida fungemia.
@ast
Do in vitro susceptibility dat ...... atients with Candida fungemia.
@en
prefLabel
Do in vitro susceptibility dat ...... atients with Candida fungemia.
@ast
Do in vitro susceptibility dat ...... atients with Candida fungemia.
@en
P2093
P356
P1476
Do in vitro susceptibility dat ...... patients with Candida fungemia
@en
P2093
A J Morris
C J Clancy
D A Sutton
M G Rinaldi
M H Nguyen
P304
P356
10.1086/514193
P407
P577
1998-02-01T00:00:00Z